Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VIBRANT

Financiado

Cerrado

In Vivo Imaging of Beta cell Receptors by Applied Nano Technology

Currently, around 30 million people in the enlarged Europe suffer from diabetes, with a prevalence of 7.5% in member states. In recent years the emergence of type 2 diabetes in children and adolescents is a new and serious health... ver más

30/06/2013

CAN

11M€

Presupuesto del proyecto: 11M€

Líder del proyecto

Centrum fur Angewandte Nanotechnologie (CAN)... No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-06-30 No tenemos la información de la convocatoria

0% 76% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

CAN

2.00M€ | Lider

Novo Nordisk

N.D. | Participante

KU Leuven

N.D. | Participante

FUNDACIO PRIVADA CENTRE DE R...

N.D. | Participante

Proyectos interesantes

DAMOC

Medical Technol...

Nanotechnology

1M€ Cerrado

UROSENSE

Nanotechnology

Medical Technol...

2M€ Cerrado

OptoBETA

Medical Technol...

Data Science

2M€ Cerrado

DPI2015-68917-R

Medical Technol...

Nanotechnology

131K€ Cerrado

PLEC2021-007727

Medical Technol...

Nanotechnology

317K€ Cerrado

NANOBreg

Medical Technol...

Nanotechnology

158K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

Centrum fur Angewandte Nanotechnologie (CAN)... No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 11M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Currently, around 30 million people in the enlarged Europe suffer from diabetes, with a prevalence of 7.5% in member states. In recent years the emergence of type 2 diabetes in children and adolescents is a new and serious health challenge to the youth of Europe, their families and society. By 2025, the number of people with diabetes is expected to rise to around 50 million in Europe, thus increasing prevalence to 10.9%. This devastating disease is ranked among the leading causes of fatal cardiovascular diseases, kidney failure, neuropathy, lower limb amputation and blindness. Estimates of annual direct cost of diabetes care in Europe are currently EUR 50 billion. The indirect costs of diabetes i.e. the cost of lost production are as high as direct costs or even higher. Diabetes results from an absolute or relative decline in pancreatic β-cell function and/or mass. Although of ultimate importance for diabetes management and the development of new therapies, hitherto, no clinically established methodology for non-invasive in vivo imaging and quantification of β-cell mass (BCM) exists. VIBRANT proposes superparamagnetic fluorous phase nanocontainers (FPNC), which are functionalized with β-cell specific ligands for in vivo MRI. This combines β-cell specific targeting with the unrivalled MRI sensitivity of supermagnetic particles and the high resolution power of 19F-containing contrast agents, and hence will outperform existing MRI technology. Furthermore, target specific drug-loaded nanocontainers will offer high potential for β-cell directed therapies. VIBRANT will offer theranostic solutions to the utmost urgent problems in the health care management of diabetes, substantially improving the early diagnosis, thus preventing distressful and costly complications, contributing to the development of new therapies for the regeneration of β-cell mass, and thus directly impacting health status and life quality of patients, health care budgets and economies within the EU.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores